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Abstract
Helicobacter pylori is an important yet unproven etiological agent of gastric cancer. H. pylori infection
is more prevalent in developing Asian countries like India and it is usually acquired at an early age.
It has been two decades since Marshall and Warren (1984) first described curved bacilli in the
stomach of ulcer and gastritis patients. This discovery has won them the Nobel Prize recently, but
the debate whether H. pylori is a pathogen or a commensal organism is still hot. Associations with
disease-specific factors remain illusive years after the genome sequences were made available.
Cytotoxin-associated antigen A (CagA) and the so-called plasticity region cluster genes are
implicated in pathogenesis of the carcinoma of stomach. Another virulence factor VacA whose role
is still debatable, has recently been projected in pathology of gastric cancer. Studies of the evolution
through genetic variation in H. pylori populations have provided a window into the history of human
population migrations and a possible co-evolution of this pathogen with its human host. Possible
symbiotic relationships were seriously debated since the discovery of this pathogen. The debate
has been further intensified as some studies proposed H. pylori infection to be beneficial in some
humans. In this commentary, we attempt to briefly discuss about H. pylori as a human pathogen, and
some of the important issues linked to its pathophysiology in different hosts.
'We dance around in a ring and suppose, the secret sits in the middle and knows' – Robert Frost
Background
Barry J. Marshall and Robin Warren, two Australian
researchers who discovered the bacterium Helicobacter
pylori in 1982 have been awarded Nobel Prize of 2005 in
Physiology or Medicine. This 'old fashioned medical
detective work' impressed the Nobel Assembly of the
Karolinska Institute, to move away from basic research
[1,2] and to reward the research that proposes a much
controversial bacterial organism as a dangerous pathogen.
It was a long-standing dogma in the medical science that
stress and lifestyle factors lead to gastritis and peptic ulcer
disease. Warren and Marshal rebutted that dogma and
made it clear that curved bacilli called Campylobacter
pyloridis (later named as Helicobacter pylori) were the main
cause of peptic ulceration, distal gastric adenocarcinoma,
and gastric lymphoma [3]. Soon after this, H. pylori colo-
nization model became one of the best-studied examples
of pathogen evolution and its role in infection biology.
This marked also the beginning of a contest on how long
H. pylori had been colonizing human stomach, promoting
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the analogy of a symbiotic organism coevolved with its
human host.
H. pylori as a marker of human peopling and migration: 
example of co-evolution
H. pylori is presumably co-evolved with its host and there-
fore, origins and expansion of multiple populations and
sub populations of H. pylori mirror ancient human migra-
tions. Ancient origins of H. pylori in the world and in India
are not clear and debatable. It is not clear how different
waves of human migrations in different continents con-
tributed to the evolution of strain diversity of H. pylori.
Our group has recently attempted to address these issues
through mapping genetic origins of H. pylori of native
Peruvians (of Amerindian ancestry) [4] and Indians (Devi
et al., unpublished data) and their genomic comparison
with hundreds of isolates from different geographic
regions. For this purpose, genetic identity of strains was
dissected by fluorescent amplified fragment length poly-
morphism (FAFLP) analysis, multilocus sequence typing
(MLST) of the housekeeping genes and the sequence anal-
yses of the babB adhesin and oipA genes. The whole cag
pathogenicity-island (cagPAI) from these strains was also
analyzed using PCR and gene sequencing. In case of South
American H. pylori populations, it was observed that while
European genotype (hp-Europe) predominated in native
Peruvian strains, approximately 20% of these strains rep-
resented a sub-population with an Amerindian ancestry
(hsp-Amerind). However, all of these strains were shown to
harbor a complete, 'western' type cagPAI, irrespective of
their ancestral affiliation and the motifs surrounding it.
This indicated a possible acquisition of cagPAI by the hsp-
Amerind strains from the European strains, during decades
of co-colonization. These observations, therefore, sug-
gested presence of ancestral H. pylori (hsp-Amerind) in
Peruvian Amerindians, which possibly managed to sur-
vive and compete against the Spanish strains that arrived
to the New World about 500 years ago. It was suggested
that this might have happened after native Peruvian H.
pylori strains acquired cagPAI sequences, either by new
acquisition in cag-negative strains or by recombination in
cag positive Amerindian strains. In case of Indian strains,
almost all the isolates analyzed revealed a European
ancestry and belonged to MLST genogroup hp-Europe.
The cagPAI harbored by Indian strains also revealed Euro-
pean features upon PCR based analysis and whole PAI
sequencing. These observations suggest that H. pylori in
India have ancient origins in Europe (Devi et al, unpub-
lished data). These results are expected to strengthen spec-
ulations related to large-scale replacement of the ancient
indigenous people of India by Indo-Aryan nomads, bring-
ing first Neolithic practices and languages from the Fertile
Crescent.
H. pylori in gastric diseases
H. pylori causes peptic ulceration, gastric adenocarcinoma,
and gastric lymphoma. Gastric adenocarcinoma is the sec-
ond highest cause of cancer deaths worldwide mainly due
to high incidence, aggressive disease course, and lack of
effective treatment options leading to a death toll of one
million per annum worldwide [3]. H. pylori is implicated
in distal gastric adenocarcinoma, which is more common
than the proximal one. H. pylori also causes B cell mucosa-
associated lymphoid tissue (MALT) lymphoma of the
stomach [3] but at the same time negatively associated
with more severe forms of reflux esophagitis and its seque-
lae – Barrett's esophagus and esophageal adenocarcinoma
[5,6]. This negative correlation is the main reason that
makes H. pylori a lesser evil. There has been a recent inter-
est to look if H. pylori causes or facilitates human diseases
of the gut other than the upper gastrointestinal tract or
syndromes like idiopathic thrombocytopenic purpura
[5,6], skin diseases, liver diseases, and cardiovascular and
cerebrovascular disease. But many of these have been
associated more commonly with Helicobacters other than
H. pylori [7,8].
Bacterial encoded proinflammatory and carcinogenic 
factors
Studies reveal that the risk for developing gastric carci-
noma was much greater with the H. pylori infection [9].
The cagA gene of H. pylori is the main virulence factor that
leads to the development of gastric adenocarcinoma
through derangement of cellular architecture and signal-
ing. Presence of a functional cagA gene determines the H.
pylori strain type to be aggressive or mild. The cagA-posi-
tive strains cause much intense ulceration of stomach or
duodenum and are more damaging than the cagA-nega-
tive ones [10] leading to atrophic gastritis and gastric car-
cinoma [11,12]. CagA, the effector protein product of
cagA, is tyrosine phosphorylated by SRC kinases after its
secretion on the intestinal mucosal surface [13]. EPIYA
motifs in the CagA protein sequence play a critical role in
tyrosine phosphorylation, which in turn activates a SHP2
phosphatase to act as a oncoprotein. As SHP2 helps in cell
growth and motility, its deregulation by CagA is an impor-
tant oncogenic mechanism encoded by H. pylori. CagA
based on sequence variation at the SHP2 binding site, is
sub-classified into two main epidemiological types – East-
Asian CagA (with stronger SHP2 binding and greater bio-
logical activity) and Western CagA (diminished SHP2
binding and milder ulcerative potentials). Strains with
multiple CagA tyrosine phosphorylation motifs are more
commonly associated with gastric cancer than those with
fewer C type motifs [14-16].
Incidence of infection with H. pylori carrying biologically
more active CagA might explain the high occurrence of
gastric carcinoma in some countries such as Japan andInfectious Agents and Cancer 2007, 2:2 http://www.infectagentscancer.com/content/2/1/2
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Korea. However, other populations with extremely high
infection rates, such as Indians have almost negligible
incidence of gastric carcinoma [17]. Possible reasons for
such strange differences of disease outcome might be
explained in the light of differences in genetic susceptibil-
ity among host populations, environmental factors such
as dietary habits, and strain differences of H. pylori.
H. pylori has a single copy of the vacA gene encoding VacA
protein, a secreted 95 kDa peptide. The vacA gene varies in
the signal sequence (alleles s1a, s1b, s1c, s2) and/or its
middle region (alleles m1, m2) among different H. pylori
populations. The different allotypes of s and m regions
determine the extent of cytotoxicity of VacA. Strains with
vacA genotype s1/m1 are more commonly associated with
gastric cancer than the other types [18]. Among other
functions, VacA has been shown to induce apoptosis in
epithelial cells. Recently, VacA has been proposed to be a
potent immunomodulatory toxin, targeting the adapted
immune system to suppress local immune responses to
prolong the outcome of infection and thus prevent clear-
ance by the host immune system [19]. The VacA has been
the subject of intense biochemistry but lacked solid evi-
dences that it is indeed involved in pathogenesis. A recent
study argues that VacA has a miniscule role as a virulence
factor during cell evasion by H. pylori. They showed that
the vacA null mutant of H. pylori was able to evade specific
cell lines, as did its wild type [20]. Therefore, the VacA
involvement is still part of a debate on its being a true vir-
ulence factor and awaits further investigation.
Apart from the cardinal virulence factors CagA and VacA,
several other proteins of the cagPAI, outer membrane
envelope proteins, flagellins, adhesins, neutrophil activat-
ing protein (NAP), porins, LPS, urease and some members
of the so called plasticity region cluster possibly playing
an important role in inflammatory processes.
Microevolution during colonization: can it be linked to 
virulence optimization?
It has long been assumed that i) the H. pylori virulence fac-
tors are stable characteristic amid an otherwise fast evolv-
ing and recombining genome and ii) that these factors can
be linked to disease progression or outcome, at any time.
However, several reports present data against these
assumptions. Two subclones of a H. pylori strain co-colo-
nized a single patient with variations in vacA mid region,
rendering one of the two sub-clones non-toxic [21]. The
reason for this was clearly the microevolution via recom-
bination within the stomach. Our group has previously
shown a large deletion in vacA gene occurring in one of
the two isolates of a common progenitor strain in a
French patient, obtained 9 years apart [22]. This was most
probably a case of adaptation or evolution in vivo. Dupli-
cation or deletion of the cagA gene has been shown by
Aras et al., [23] in two isolates existing in one individual
and recovered 7 years apart. Kersulyte et al, have shown
complete deletion of cagPAI through recombination [24].
In addition, various genotyping methods applied to two
or more H. pylori isolates obtained from the same patient
revealed similar fingerprints, with minor differences
[25,26]. This may be possible due to the fact that two or
more isolates recovered from a patient may share an
ancestral relationship with a founder strain but have
undergone independent genomic alterations. This phe-
nomenon has been termed as 'microevolution' [25,27].
However, sequence evidence is necessary to confirm the
location and extent of microevolution and phenotypic
confirmation [16] is required to ascertain if such microev-
olution leads to alteration or optimization of virulence in
response to change in the gastric environment.
Host genetic factors in H. pylori induced carcinoma
Host factors also play an important role in predisposition
to H. pylori induced diseases and susceptibilities towards
severe pathological outcomes. The host factors relevant in
H. pylori induced diseases mainly include components of
gastric secretion system and the immune apparatus. Inter-
estingly, the gastritis and ulcer disease that result from
bacterial infection, have distinct clinical profiles and are
inversely associated with a high degree of acid secretion,
whereas, gastric cancers are associated with low acid secre-
tion due to loss of parietal cell mass [28,29]. In a recent
study involving an East Indian population, authors sug-
gested an association between the IL1β gene polymor-
phisms and H. pylori-mediated duodenal ulcer risk. They
further observed effects of specific IL1β genotypes on the
expression of IL1β mRNA in the gastric mucosa. Their in
vivo studies were further substantiated, for the first time,
by  in vitro experiments, which represent the opposite
homozygous risk genotypes that were observed in duode-
nal ulcer patients [30]. So this might explain the fact that
differences in carcinogenesis risk in people from different
geographical areas might reflect differences in their
genetic make up.
The developing country enigma: Indians, diet and 
predisposition to gastric cancer?
What is enigmatic about the gastric cancer scenario in
India? The answer is not simple. This country has a high
prevalence of H. pylori infections and a low risk of gastric
cancer in contrast to some of the developed countries with
a low H. pylori colonization rate like China and Japan.
India is known for a very high incidence of H. pylori infec-
tion [31,32]. Biologically inactive CagA could be a con-
tributory factor in low prevalence of gastric ulcers and
cancer in India. However, phenotyping studies based on
in vitro assessment of CagA function in Indian isolates
have not been done. In our opinion it will be inappropri-
ate to implicate CagA functionality alone. The spectrumInfectious Agents and Cancer 2007, 2:2 http://www.infectagentscancer.com/content/2/1/2
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and outcome of pathology in H. pylori infection is intri-
cately governed by all the three factors – virulence, host
genetics and the environment. It appears that the environ-
ment of stomach (acidity, buffering and mucus content)
governed by lifestyle factors (diet, food habits, alcohol-
ism, oral hygiene, water hygiene, personal hygiene, prox-
imity with farming communities and animals) and the
genetic determinants of susceptibility are chief drivers of
the pathological outcome. Although poverty-associated
factors (overcrowding, poor sanitation, lower socioeco-
nomic status, compromised water hygiene etc.) in coun-
tries like India facilitate high frequency of H. pylori
colonization, rapid re-colonization post eradication and
lower age of acquisition [33]; a surprising fact is that such
areas are at lowest risk of developing gastric cancer [34].
Correlation between H. pylori infection and gastric cancer
has so far been unsuccessful in India [35]. A recent study
from India involving 279 patients with gastric neoplasms
failed to show a higher prevalence of H. pylori infection in
patients with gastric neoplasms as compared to the con-
trols (101 non-ulcer dyspepsia and 355 healthy subjects)
[36]. These observations challenge the versatility of sim-
plified models of gastric carcinogenesis based on H. pylori
infection. We believe that in Indian context, diet as a
major environmental factor governs the dynamics of gas-
tric cancer demography mainly by regulating physiologi-
cal integrity of gastric mucosal niches. And that is where;
the dietary practices and lifestyle factors become impor-
tant in the context of progression from gastritis to gastric
cancer. Diets low in vegetables, fibers and fruits and high
in salt-preserved foods or salt-processed meat increase the
risk of stomach cancer [37].
Accordingly, in such situations there seems to be a differ-
ence in the distribution frequency of gastric cancer inci-
dence. The southern and eastern parts of India have higher
frequency of gastric cancer than rest of the country [38].
Rice is the staple food in south, whereas fish, meat, spices
and salts are the main food items in eastern part [37-39].
Contrastingly, the large vegetarian population in northern
India is at lower risk of gastric cancer. But the times are
changing; rapid flourish of post globalization corporate
culture brought fast foods, germ-free bottled water, pas-
teurized milk and preserved meat items to the present day
lifestyle in big Indian cities. However, it will be too early
to link it with rising gastric cancer incidences in cities in
India [39].
Conversely, low to negligible incidence of gastric cancer as
recorded for rural areas in India by the national cancer
registry [39] leads us to speculate why rural communities
have distinct advantages in terms of less damages from H.
pylori infection. It needs to be investigated if these advan-
tages are due to their diet based on fresh farm produce and
their 'friendship' with the so-called "old friends", the
group of bacteria that might be maintaining levels of reg-
ulatory immune cell populations and have been intri-
cately associated during most of the mammalian
evolution.
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